This report provides a comprehensive analysis of the global RNAi Therapeutics market, projecting significant growth through 2032. It examines the industry landscape by dissecting molecular modalities, delivery methods, and diverse applications ranging from cardiovascular diseases to oncology. Furthermore, the study evaluates key regional trends, competitive strategies of leading biopharma companies, and evolving business models. By analyzing technological advancements in oligonucleotide chemistry and delivery systems, the report identifies emerging opportunities and critical drivers shaping the future of gene-silencing therapeutics.

Market Overview

The global RNAi Therapeutics market is projected to experience significant growth, increasing from US$ 944 million in 2025 to US$ 3164 million by 2032. The market is expected to expand at a CAGR of 19.6% from 2026 to 2032.

Definition and Technology: RNAi Therapeutics refers to drugs that harness RNA interference to silence disease-causing genes, primarily through small interfering RNA (siRNA), short hairpin RNA (shRNA), or related constructs. By selectively degrading target mRNA, RNAi enables precise, durable suppression of protein expression that is difficult to achieve with small molecules or antibodies. The field has matured from platform science to commercial reality, driven by advances in chemical stabilization, conjugation (e.g., receptor-mediated uptake), and clinically validated targets.

Value Chain and Industry Dynamics

Upstream and Manufacturing

• Upstream Inputs: Oligonucleotide chemistry, nucleotide building blocks, delivery technologies (conjugates, nanoparticles, vectors), and enabling IP around target discovery and bioinformatics.
• Manufacturing: Relies on specialized oligo synthesis, purification, and formulation under GMP.

Downstream and End Markets

• Development Models: RNAi therapeutics are developed by integrated biopharma companies or via partnerships with large pharma for late-stage trials and commercialization.
• End Markets: Metabolic and liver diseases, cardiovascular conditions, oncology, and rare genetic disorders.
• Primary Channels: Hospitals and specialty clinics.

Economic Analysis: Gross Margins

Gross margins for RNAi therapeutics are structurally attractive but heterogeneous:

• Commercialized siRNA Drugs: Can achieve ~70–85% gross margins as processes scale, yields improve, and conjugate-based delivery reduces formulation complexity.
• Margin Headwinds: High COGS for complex chemistries, cold-chain logistics, and royalties tied to foundational IP.
• Early-stage Programs: Exhibit lower effective margins due to small batch sizes and high quality control intensity.
• Mature Assets: Benefit from learning curves and supplier consolidation.

Report Scope and Methodology

LPI (LP Information)’s newest research report, the “RNAi Therapeutics Industry Forecast,” reviews total world RNAi Therapeutics sales in 2025 and provides a comprehensive analysis by region and market sector of projected RNAi Therapeutics sales for 2026 through 2032. The report provides a detailed analysis in US$ millions of the world RNAi Therapeutics industry, with sales broken down by region, market sector, and sub-sector.

Key Analytical Focus Areas:

• Landscape Analysis: Comprehensive analysis of the global RNAi Therapeutics landscape, highlighting key trends related to product segmentation, company formation, revenue, market share, latest developments, and M&A activity.
• Strategic Analysis: Evaluation of the strategies of leading global companies, focusing on RNAi Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints.
• Market Drivers: Evaluation of key market trends, drivers, and affecting factors shaping the global outlook.
• Methodology: A transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, offering a nuanced view of the current state and future trajectory of the global RNAi Therapeutics market.

Market Segmentation

By Type

• Subcutaneous Injection
• Intravenous Infusion

By Molecular Modality

• Synthetic siRNA
• shRNA / ddRNAi
• miRNA Mimics / Inhibitors
• bi-shRNA / bifunctional RNAi
• Self-delivering RNAi

By Business Model

• Fully Integrated Biopharma
• Platform-driven Licensing Model
• Co-development / Profit-sharing Model
• Others

By Application

• Cardiovascular Disease
• Genetic Disorder
• Cancer
• Other

Regional Segmentation

Americas

• United States
• Canada
• Mexico
• Brazil

APAC

• China
• Japan
• Korea
• Southeast Asia
• India
• Australia

Europe

• Germany
• France
• UK
• Italy
• Russia

Middle East & Africa

• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Competitive Landscape

The following companies are profiled based on primary expert inputs and analysis of company coverage, product portfolio, and market penetration:

• Alnylam Pharmaceuticals
• Arrowhead Pharmaceuticals
• Silence Therapeutics
• Benitec Biopharma
• Phio Pharmaceuticals
• RXi Pharmaceuticals
• Arrakis Therapeutics
• miRagen Therapeutics
• Sylentis
• Gradalis
• Sirnaomics
• Silenseed
• Silexion Therapeutics
• Novartis
• Novo Nordisk
• Roche
• Sanofi
• Regeneron Pharmaceuticals

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global RNAi Therapeutics Market Size (2021-2032)

    • 2.1.2 RNAi Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for RNAi Therapeutics by Country/Region (2021, 2025 & 2032)

  • 2.2 RNAi Therapeutics Segment by Type

    • 2.2.1 Subcutaneous Injection

    • 2.2.2 Intravenous Infusion

    • 2.2.3 RNAi Therapeutics Market Size by Type

      • 2.2.3.1 RNAi Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.3.2 Global RNAi Therapeutics Market Size Market Share by Type (2021-2026)

  • 2.3 RNAi Therapeutics Segment by Molecular Modality

    • 2.3.1 Synthetic siRNA

    • 2.3.2 shRNA / ddRNAi

    • 2.3.3 miRNA Mimics / Inhibitors

    • 2.3.4 bi-shRNA / bifunctional RNAi

    • 2.3.5 Self-delivering RNAi

    • 2.3.6 RNAi Therapeutics Market Size by Molecular Modality

      • 2.3.6.1 RNAi Therapeutics Market Size CAGR by Molecular Modality (2021 VS 2025 VS 2032)
      • 2.3.6.2 Global RNAi Therapeutics Market Size Market Share by Molecular Modality (2021-2026)

  • 2.4 RNAi Therapeutics Segment by Business Model

    • 2.4.1 Fully Integrated Biopharma

    • 2.4.2 Platform-driven Licensing Model

    • 2.4.3 Co-development / Profit-sharing Model

    • 2.4.4 Others

    • 2.4.5 RNAi Therapeutics Market Size by Business Model

      • 2.4.5.1 RNAi Therapeutics Market Size CAGR by Business Model (2021 VS 2025 VS 2032)
      • 2.4.5.2 Global RNAi Therapeutics Market Size Market Share by Business Model (2021-2026)

  • 2.5 RNAi Therapeutics Segment by Application

    • 2.5.1 Cardiovascular Disease

    • 2.5.2 Genetic Disorder

    • 2.5.3 Cancer

    • 2.5.4 Other

    • 2.5.5 RNAi Therapeutics Market Size by Application

      • 2.5.5.1 RNAi Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.5.5.2 Global RNAi Therapeutics Market Size Market Share by Application (2021-2026)

• 3 RNAi Therapeutics Market Size by Player

  • 3.1 RNAi Therapeutics Market Size Market Share by Player

    • 3.1.1 Global RNAi Therapeutics Revenue by Player (2021-2026)

    • 3.1.2 Global RNAi Therapeutics Revenue Market Share by Player (2021-2026)

  • 3.2 Global RNAi Therapeutics Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 RNAi Therapeutics by Region

  • 4.1 RNAi Therapeutics Market Size by Region (2021-2026)

  • 4.2 Global RNAi Therapeutics Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas RNAi Therapeutics Market Size Growth (2021-2026)

  • 4.4 APAC RNAi Therapeutics Market Size Growth (2021-2026)

  • 4.5 Europe RNAi Therapeutics Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa RNAi Therapeutics Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas RNAi Therapeutics Market Size by Country (2021-2026)

  • 5.2 Americas RNAi Therapeutics Market Size by Type (2021-2026)

  • 5.3 Americas RNAi Therapeutics Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC RNAi Therapeutics Market Size by Region (2021-2026)

  • 6.2 APAC RNAi Therapeutics Market Size by Type (2021-2026)

  • 6.3 APAC RNAi Therapeutics Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe RNAi Therapeutics Market Size by Country (2021-2026)

  • 7.2 Europe RNAi Therapeutics Market Size by Type (2021-2026)

  • 7.3 Europe RNAi Therapeutics Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa RNAi Therapeutics by Region (2021-2026)

  • 8.2 Middle East & Africa RNAi Therapeutics Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa RNAi Therapeutics Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global RNAi Therapeutics Market Forecast

  • 10.1 Global RNAi Therapeutics Forecast by Region (2027-2032)

    • 10.1.1 Global RNAi Therapeutics Forecast by Region (2027-2032)

    • 10.1.2 Americas RNAi Therapeutics Forecast

    • 10.1.3 APAC RNAi Therapeutics Forecast

    • 10.1.4 Europe RNAi Therapeutics Forecast

    • 10.1.5 Middle East & Africa RNAi Therapeutics Forecast

  • 10.2 Americas RNAi Therapeutics Forecast by Country (2027-2032)

    • 10.2.1 United States Market RNAi Therapeutics Forecast

    • 10.2.2 Canada Market RNAi Therapeutics Forecast

    • 10.2.3 Mexico Market RNAi Therapeutics Forecast

    • 10.2.4 Brazil Market RNAi Therapeutics Forecast

  • 10.3 APAC RNAi Therapeutics Forecast by Region (2027-2032)

    • 10.3.1 China RNAi Therapeutics Market Forecast

    • 10.3.2 Japan Market RNAi Therapeutics Forecast

    • 10.3.3 Korea Market RNAi Therapeutics Forecast

    • 10.3.4 Southeast Asia Market RNAi Therapeutics Forecast

    • 10.3.5 India Market RNAi Therapeutics Forecast

    • 10.3.6 Australia Market RNAi Therapeutics Forecast

  • 10.4 Europe RNAi Therapeutics Forecast by Country (2027-2032)

    • 10.4.1 Germany Market RNAi Therapeutics Forecast

    • 10.4.2 France Market RNAi Therapeutics Forecast

    • 10.4.3 UK Market RNAi Therapeutics Forecast

    • 10.4.4 Italy Market RNAi Therapeutics Forecast

    • 10.4.5 Russia Market RNAi Therapeutics Forecast

  • 10.5 Middle East & Africa RNAi Therapeutics Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market RNAi Therapeutics Forecast

    • 10.5.2 South Africa Market RNAi Therapeutics Forecast

    • 10.5.3 Israel Market RNAi Therapeutics Forecast

    • 10.5.4 Turkey Market RNAi Therapeutics Forecast

  • 10.6 Global RNAi Therapeutics Forecast by Type (2027-2032)

  • 10.7 Global RNAi Therapeutics Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market RNAi Therapeutics Forecast

• 11 Key Players Analysis

  • 11.1 Alnylam Pharmaceuticals

    • 11.1.1 Alnylam Pharmaceuticals Company Information

    • 11.1.2 Alnylam Pharmaceuticals RNAi Therapeutics Product Offered

    • 11.1.3 Alnylam Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 Alnylam Pharmaceuticals Main Business Overview

    • 11.1.5 Alnylam Pharmaceuticals Latest Developments

  • 11.2 Arrowhead Pharmaceuticals

    • 11.2.1 Arrowhead Pharmaceuticals Company Information

    • 11.2.2 Arrowhead Pharmaceuticals RNAi Therapeutics Product Offered

    • 11.2.3 Arrowhead Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 Arrowhead Pharmaceuticals Main Business Overview

    • 11.2.5 Arrowhead Pharmaceuticals Latest Developments

  • 11.3 Silence Therapeutics

    • 11.3.1 Silence Therapeutics Company Information

    • 11.3.2 Silence Therapeutics RNAi Therapeutics Product Offered

    • 11.3.3 Silence Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Silence Therapeutics Main Business Overview

    • 11.3.5 Silence Therapeutics Latest Developments

  • 11.4 Benitec Biopharma

    • 11.4.1 Benitec Biopharma Company Information

    • 11.4.2 Benitec Biopharma RNAi Therapeutics Product Offered

    • 11.4.3 Benitec Biopharma RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 Benitec Biopharma Main Business Overview

    • 11.4.5 Benitec Biopharma Latest Developments

  • 11.5 Phio Pharmaceuticals

    • 11.5.1 Phio Pharmaceuticals Company Information

    • 11.5.2 Phio Pharmaceuticals RNAi Therapeutics Product Offered

    • 11.5.3 Phio Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 Phio Pharmaceuticals Main Business Overview

    • 11.5.5 Phio Pharmaceuticals Latest Developments

  • 11.6 RXi Pharmaceuticals

    • 11.6.1 RXi Pharmaceuticals Company Information

    • 11.6.2 RXi Pharmaceuticals RNAi Therapeutics Product Offered

    • 11.6.3 RXi Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 RXi Pharmaceuticals Main Business Overview

    • 11.6.5 RXi Pharmaceuticals Latest Developments

  • 11.7 Arrakis Therapeutics

    • 11.7.1 Arrakis Therapeutics Company Information

    • 11.7.2 Arrakis Therapeutics RNAi Therapeutics Product Offered

    • 11.7.3 Arrakis Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.7.4 Arrakis Therapeutics Main Business Overview

    • 11.7.5 Arrakis Therapeutics Latest Developments

  • 11.8 miRagen Therapeutics

    • 11.8.1 miRagen Therapeutics Company Information

    • 11.8.2 miRagen Therapeutics RNAi Therapeutics Product Offered

    • 11.8.3 miRagen Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.8.4 miRagen Therapeutics Main Business Overview

    • 11.8.5 miRagen Therapeutics Latest Developments

  • 11.9 Sylentis

    • 11.9.1 Sylentis Company Information

    • 11.9.2 Sylentis RNAi Therapeutics Product Offered

    • 11.9.3 Sylentis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.9.4 Sylentis Main Business Overview

    • 11.9.5 Sylentis Latest Developments

  • 11.10 Gradalis

    • 11.10.1 Gradalis Company Information

    • 11.10.2 Gradalis RNAi Therapeutics Product Offered

    • 11.10.3 Gradalis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.10.4 Gradalis Main Business Overview

    • 11.10.5 Gradalis Latest Developments

  • 11.11 Sirnaomics

    • 11.11.1 Sirnaomics Company Information

    • 11.11.2 Sirnaomics RNAi Therapeutics Product Offered

    • 11.11.3 Sirnaomics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.11.4 Sirnaomics Main Business Overview

    • 11.11.5 Sirnaomics Latest Developments

  • 11.12 Silenseed

    • 11.12.1 Silenseed Company Information

    • 11.12.2 Silenseed RNAi Therapeutics Product Offered

    • 11.12.3 Silenseed RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.12.4 Silenseed Main Business Overview

    • 11.12.5 Silenseed Latest Developments

  • 11.13 Silexion Therapeutics

    • 11.13.1 Silexion Therapeutics Company Information

    • 11.13.2 Silexion Therapeutics RNAi Therapeutics Product Offered

    • 11.13.3 Silexion Therapeutics RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.13.4 Silexion Therapeutics Main Business Overview

    • 11.13.5 Silexion Therapeutics Latest Developments

  • 11.14 Novartis

    • 11.14.1 Novartis Company Information

    • 11.14.2 Novartis RNAi Therapeutics Product Offered

    • 11.14.3 Novartis RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.14.4 Novartis Main Business Overview

    • 11.14.5 Novartis Latest Developments

  • 11.15 Novo Nordisk

    • 11.15.1 Novo Nordisk Company Information

    • 11.15.2 Novo Nordisk RNAi Therapeutics Product Offered

    • 11.15.3 Novo Nordisk RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.15.4 Novo Nordisk Main Business Overview

    • 11.15.5 Novo Nordisk Latest Developments

  • 11.16 Roche

    • 11.16.1 Roche Company Information

    • 11.16.2 Roche RNAi Therapeutics Product Offered

    • 11.16.3 Roche RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.16.4 Roche Main Business Overview

    • 11.16.5 Roche Latest Developments

  • 11.17 Sanofi

    • 11.17.1 Sanofi Company Information

    • 11.17.2 Sanofi RNAi Therapeutics Product Offered

    • 11.17.3 Sanofi RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.17.4 Sanofi Main Business Overview

    • 11.17.5 Sanofi Latest Developments

  • 11.18 Regeneron Pharmaceuticals

    • 11.18.1 Regeneron Pharmaceuticals Company Information

    • 11.18.2 Regeneron Pharmaceuticals RNAi Therapeutics Product Offered

    • 11.18.3 Regeneron Pharmaceuticals RNAi Therapeutics Revenue, Gross Margin and Market Share (2021-2026)

    • 11.18.4 Regeneron Pharmaceuticals Main Business Overview

    • 11.18.5 Regeneron Pharmaceuticals Latest Developments

• 12 Research Findings and Conclusion